{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-011441","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2025-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.754019+00:00","generated_at":"2026-05-18T00:46:33.575886+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AIM ImmunoTech reports positive mid-year Phase 2 data for Ampligen+Imfinzi in pancreatic cancer","bullets":["No grade ≥2 immune-related or systemic toxicities reported across 14 enrolled patients.","3 of 14 patients (21%) had PFS >6 months; 3 additional patients not yet progressed at cutoff.","Of 11 evaluable patients, 7 (64%) achieved overall survival >6 months.","Combination of Ampligen (rintatolimod) and AstraZeneca's Imfinzi (durvalumab) studied post-FOLFIRINOX.","Final analysis pending immune-monitoring data from paired biopsies and blood samples."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-011441","json":"https://secwatch.observer/filing/0001493152-25-011441.json","markdown":"https://secwatch.observer/filing/0001493152-25-011441.md","text":"https://secwatch.observer/filing/0001493152-25-011441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315225011441/0001493152-25-011441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315225011441/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T00:46:33.575886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}